Newsroom


Please note that the Company does not update, correct or revise news releases after they have been issued. For the most current information about the Company, please refer to the most recent releases.
29

Bausch + Lomb Highlights Scientific and Clinical Research during the Association for Research in Vision and Ophthalmology Annual Meeting in Seattle, WA

 

FOR RELEASE FRIDAY, APRIL 29, 2016

BRIDGEWATER, NJ — Bausch + Lomb, a leading global eye health company, announced today that eight scientific posters will address the results of a variety of research studies, which feature several of the company’s current product offerings and pipeline programs in its pharmaceuticals business, during the Association for Research in Vision and Ophthalmology (ARVO) Annual meeting in Seattle, WA (May 1-5).   

We are committed to conducting research and exploring scientific advancements that help advance our current product portfolio and identify potential future therapies to help meet the needs of our customers and their patients,” said Cal Roberts, M.D., chief medical officer, Bausch + Lomb. “Each year, ARVO provides an excellent forum to share our latest research findings and foster dialogue within the eye care community to ultimately help bring novel treatments and products to market.”

The research supported by Bausch + Lomb covers a variety of therapeutic areas including Sjögren’s syndrome, Intraocular Pressure (IOP) lowering, and ocular infection and inflammation. Highlights of this new research include:

  • Preliminary 2015 results from the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study, the only ongoing nationwide program that monitors the in vitro potency of a variety of common antibiotics against ocular pathogens;
  • A study of the sensitivity and specificity of the Sjö® test, a diagnostic panel which incorporates three proprietary biomarkers in addition to traditional biomarkers to allow early detection of Sjögren’s Syndrome;
  • A report on the overall incidence of clinically significant (≥10 mm Hg) IOP elevations across multiple clinical studies with the use of loteprednol etabonate;
  • Four clinical presentations evaluating the safety and IOP-lowering efficacy of latanoprostene bunod ophthalmic solution 0.024% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT);
    • In comparison to timolol maleate ophthalmic solution 0.5% in a randomized controlled trial;
    • In a pooled analysis of two randomized controlled trials in comparison to timolol maleate ophthalmic solution 0.5%;
    • In the open-label safety and efficacy extension phase of two randomized controlled trials;
    • In a long-term, single-arm, open-label study of Japanese subjects.


The complete schedule (by topic) for all poster presentations that will include Bausch + Lomb products and pipeline programs during the meeting include:

Ocular Inflammation


  • Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure.”  Cavet, Megan E.; DeCory, Heleen H.; Sheppard, John D.  [Wednesday, May 4, 2016, 3:45-5.30 p.m. PT, Session 475, Poster 5405-B0145].

Ocular Infection

  • “Antibiotic Resistance Profiles of Ocular Pathogens – An Update from the 2015 ARMOR Surveillance Study.”  Sanfilippo, Christine M.; DeCory, Heleen H.; Sahm, Daniel F.; Asbell, Penny A. [Wednesday May 4, 2016, 3:45-5.30 p.m. PT, Session 475, Poster 5404-B0144].
  • In Vitro Antibiotic Susceptibility of Ocular Pathogens Collected from the Aqueous and Vitreous Humor during the ARMOR Surveillance Study.”  Asbell, Penny A.; DeCory, Heleen H.; Sahm, Daniel F.; Sanfilippo, Christine M.  [Monday, May 2, 2016, 3:45-5.30 p.m. PT, Session 272, Poster 2348-A0015].

Sjögren’s Syndrome

  • Early Detection of Sjögren’s Syndrome; Sensitivity and Specificity of the Sjö® Diagnostic Test.”Shen, Long; Malyavantham, Kishore; Suresh, Lakshmanan; Kapsogeorgou, Efstathia K.; Tzioufas, Anthanasios G.; Sun, Yuechi; Wang, Ying; Shi, Guixiu.  [Thursday May 5, 2016, 8.00-9.45 PM, Session 503, Poster 5681-A0027].

IOP Lowering

  • Efficacy of Latanoprostene Bunod 0.024% vs. Timolol Maleate 0.5% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: the LUNAR Study.”  Peace, James H.; Medeiros, Felipe A.; Martin, Keith R.; Vittitow, Jason L.; Weinreb, Robert N. [Tuesday, May 3, 2016, 8:30-10:15 a.m. PT, Session 314, Poster 3035-A0384].
  • “Integrated Efficacy of Latanoprostene Bunod 0.024% vs. Timolol Maleate 0.5% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies.”  Kaufman, Paul L.; Liebmann, Jeffrey M.; Vittitow, Jason L.; Weinreb, Robert N.  [Tuesday, May 3, 2016, 8:30-10:15 a.m. PT, Session 314, Poster 3036-A0385].
  • Long-term Efficacy and Safety of Latanoprostene Bunod 0.024% for Intraocular Pressure Lowering in Patients with Open-Angle Glaucoma or Ocular Hypertension: APOLLO and LUNAR Studies.”  Vittitow, Jason L.; Liebmann, Jeffrey M.; Kaufman, Paul L.; Medeiros, Felipe A.; Martin, Keith R.; Weinreb, Robert N.  [Tuesday, May 3, 2016, 8:30-10:15 a.m. PT, Session 314, Poster 3030-A0379].
  • Long-term Safety and Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: the JUPITER Study.” Kawase, Kazuhide; Vittitow, Jason L.; Yamamoto, Tetsuya; Araie, Makoto.  [Tuesday, May 3, 2016, 8:30-10:15 a.m. PT, Session 314, Poster 3037-A0386].

 

Important Safety Information for Lotemax® Gel

  • Lotemax Gel is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.
  • Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored.
  • Use of corticosteroids may result in posterior subcapsular cataract formation.
  • Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation and occurrence of perforations in those with diseases causing corneal and scleral thinning. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification, and where appropriate, fluorescein staining.
  • Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infection. In acute purulent conditions, steroids may mask infection or enhance existing infections.
  • Use of corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and exacerbate the severity of many viral infections of the eye (including herpes simplex).
  • Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application.
  • Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use.
  • Patients should not wear contact lenses when using Lotemax Gel.
  • The most common ocular adverse drug reactions were anterior chamber inflammation (5 percent), eye pain (2 percent) and foreign body sensation (2 percent).


Please click
here for Prescribing Information.

About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.

 

Sjö is a trademark of Bausch & Lomb Incorporated or its affiliates.

All other brand/product names are trademarks of their respective owners.
© 2016 Bausch & Lomb Incorporated.
BES.0070.USA.16

 

 

# # #

News Media Contacts
Kristy Marks
PR Product Manager, Bausch + Lomb
(585) 338-8095 or
kristy.marks@bausch.com

Teresa Panas
BioComm Network, on behalf of Bausch + Lomb
(973) 809-8590 or tpanas@biocommnetwork.com

Michele Gray
BioComm Network, on behalf of Bausch + Lomb
(917) 449-9250 or
michele_gray@me.com

Actions: E-mail | Permalink |